The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients treated ...

The monoclonal antibody (mAb) helped maintain safe platelet levels for a prolonged period, reducing patient reliance on ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

Novartis (NYSE:NVS) (SIX:NOVN) said its experimental antibody ianalumab, used in combination with eltrombopag, achieved the ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...

The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a ...

Results from the Phase III NEPTUNUS-1 (NCT05350072) and NEPTUNUS-2 (NCT05349214) trials demonstrated that ianalumab ...

If approved, Novartis' ianalumab would become the first targeted treatment for patients with Sjögren’s disease.